Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.

doi:10.1016/j.mayocp.2023.11.019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.

Mayo Clinic proceedings - 1 Feb 2024

Giudicessi John R, Alsidawi Said, Geske Jeffrey B, Newman Darrell B, Arruda-Olson Adelaide M, Bos J Martijn, Ommen Steve R, Ackerman Michael J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzylamines
Share to Cardiomyopathy, Hypertrophic
Share to Genotype
Share to Uracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 38309941
DOI: 10.1016/j.mayocp.2023.11.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.PMID 38309941Read ↗

French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of MavacamtenSemantic proximity Read ↗

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy.Semantic proximity Read ↗

Impact of common β1-adrenergic receptor polymorphisms on the interaction with agonistic autoantibodies in dilated cardiomyopathy.Semantic proximity Read ↗

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes.Semantic proximity Read ↗

Advances in molecular genetics and management of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Genetics of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy.Semantic proximity Read ↗

Clinical Challenges of Genotype Positive (+)–Phenotype Negative (−) Family Members in Hypertrophic CardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.